Additionally, previous research has revealed that EpCAM forms a complex with p85, the regulatory subunit of PI3K [36], and promotes tumor progression in prostate cancer and nasopharyngeal carcinoma through the regulation of the PI3K/AKT/mTOR pathway [57,58,59]. Here, EPCAM is linked to prostate carcinoma.